Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors
暂无分享,去创建一个
T. Ishida | Kei Kawada | K. Jobu | Naohisa Tamura | M. Miyamura | S. Yoshioka | Masafumi Okazaki | Shumpei Morisawa | Shouhei Sugimoto
[1] Cassie S. Mitchell,et al. Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia , 2021, Cancers.
[2] T. Ishida,et al. Risk Factors for Pseudoaldosteronism with Yokukansan Use: Analysis Using the Japanese Adverse Drug Report (JADER) Database. , 2020, Biological & pharmaceutical bulletin.
[3] Y. Kinosada,et al. Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database , 2019, International journal of medical sciences.
[4] R. Saxena,et al. Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia. , 2019, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[5] Á. Illés,et al. Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia , 2018, Platelets.
[6] Y. Kinosada,et al. Evaluation of Drug-Induced Photosensitivity Using the Japanese Adverse Drug Event Report (JADER) Database. , 2017, Biological & pharmaceutical bulletin.
[7] S. Mustjoki,et al. Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner , 2017, Clinical Cancer Research.
[8] S. Kimura,et al. Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg , 2017, Clinical lymphoma, myeloma & leukemia.
[9] G. Bar-Sela,et al. Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review. , 2016, Anticancer research.
[10] H. Prince,et al. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report , 2015, Platelets.
[11] Y. Kinosada,et al. Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. , 2015, Biological & pharmaceutical bulletin.
[12] M. Molokhia,et al. Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data , 2013, Drug Safety.
[13] M. Baccarani,et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.
[14] R. Latagliata,et al. "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. , 2010, Leukemia research.
[15] P. Ding,et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. , 2010, Leukemia research.
[16] M. Gordon. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .
[17] C. Récher,et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. , 2009, Blood.
[18] H. Kantarjian,et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. , 2009, Blood.
[19] H. Kantarjian,et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy , 2009, Cancer.
[20] M. Cameron,et al. Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways , 2009, Drug Metabolism and Disposition.
[21] Ulrich Klotz,et al. Pharmacokinetics and drug metabolism in the elderly , 2009, Drug metabolism reviews.
[22] P. Nürnberg,et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. , 2007, Pharmacogenomics.
[23] M. Baccarani,et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. , 2007, Haematologica.
[24] Kenneth J Rothman,et al. The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.
[25] Peter Neuhaus,et al. Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.
[26] M. Lindquist,et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.